Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2015

View Archived Issues

Astellas Pharma presents milestones of fourth quarter of fiscal 2014

Sun Biomedical agrees to acquire Dimerix Bioscience

Eisai patents FGFR-4 inhibitors

Angion Biomedica plans phase III trial of BB3 in delayed kidney graft function

Tonix Pharmaceuticals starts phase III trial of TNX-102 SL for fibromyalgia

Dicerna expands phase I trial of DCR-MYC to include PNET cohort

Discovery Labs' phase IIa study of Aerosurf meets key objectives

Luye Pharma completes three studies for risperidone extended-release microspheres

FDA grants fast track designation to TRC-105 for renal cell carcinoma

Xadago launched in Germany for mid- to late-stage Parkinson's disease

ISIS-664844 selectively targets the P23H variant of Rhodopsin

Vaccination with FSPs shows potential for the treatment of MSI-H CRC

FDA approves Treximet for use in pediatric migraine

Novartis reports development of complement factor B inhibitors

FORUM Pharmaceuticals patents nAChR alpha7 agonists

Chugai discloses DDR1 inhibitors

Taisho develops antibacterial hydroxamic acids

Boehringer Ingelheim exercises option for Pharmaxis drug candidate

Preliminary phase I trial results presented on DC vaccination therapy for AML

Selecta and Genethon to investigate technology enabling repeat dosing of gene therapies

Alnylam files for permission to start phase I/II trial of alpha1-antitrypsin RNAi therapeutic

Mitsubishi Tanabe files application in Japan for Remicade in Kawasaki disease

Sacituzumab govitecan awarded FDA fast track designation for NSCLC

Bristol-Myers Squibb's IPN-007 receives U.S. orphan status for progressive supranuclear palsy

Prostanoid EP2/3 agonist ONO-8055: a promising agent for underactive bladder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...